Clinical Testing News and Research

RSS

ULURU fourth quarter net loss decreases to $0.3 million

ULURU Inc. today announced its financial results for the fourth quarter and year ended December 31, 2010.

1 Apr 2011

Adeona reports $3,164,512 net revenue for 2010

Adeona Pharmaceuticals, Inc., a developer of innovative medicines for serious central nervous system diseases, reported its financial results for the year ended December 31, 2010, as well as updates since the beginning of the 4th quarter.

31 Mar 2011

Non-invasive blood glucose monitor closer to market

People with diabetes could soon have a pain-free way to check their blood glucose levels. Researchers at the University of Missouri–St. Louis have developed a portable, inexpensive non-invasive blood glucose detector. The university has licensed patent rights for the device to St. Louis Medical Devices, Inc., a Missouri company headquartered at UMSL’s own startup company incubator – IT Enterprises, to bring the device to market.

30 Mar 2011

FDA grants orphan drug status to America Stem Cell's ASC-101

America Stem Cell, Inc. announced today that the U.S. Food and Drug Administration has granted Orphan Drug Designation to ASC-101 to improve homing to bone marrow in patients receiving hematopoietic stem cell transplantation.

30 Mar 2011

Concert initiates CTP-499 Phase 1 study in patients with diabetic nephropathy

Concert Pharmaceuticals, Inc. today announced it has made significant progress advancing CTP-499, its novel anti-inflammatory, anti-oxidant, and anti-fibrotic agent for diabetic nephropathy and other forms of chronic kidney disease, into clinical development.

29 Mar 2011

Dosing commences in Phase I clinical study of GenSpera's G-202 at Cancer Therapy & Research Center

GenSpera, Inc. announced that the first patient was dosed in the ongoing Phase I clinical study of its chemotherapeutic agent, G-202, at the Cancer Therapy & Research Center (CTRC) at The University of Texas Health Science Center at San Antonio in San Antonio, Texas.

28 Mar 2011

CPRIT awards Bellicum $5.7 million to advance CaspaCIDe therapy for late stage cancer

Bellicum Pharmaceuticals, Inc. today announced that the Company received notice of a $5.7 million company commercialization award from the Cancer Prevention and Research Institute of Texas ("CPRIT"). Bellicum was the only company recommended for funding in this second round of the commercialization award program.

25 Mar 2011

EU supports new collaborative research projects on tuberculosis

It's March 24th again and the World Tuberculosis Day reminds us that for almost 50 years no new drugs have been developed against this terrible disease, which is currently killing nearly two million people worldwide each year. It's a global problem because the emergence of drug resistant strains of this infectious disease - normally associated with poverty - is a growing problem even in high-income economies.

25 Mar 2011

MnSOD oral drug can protect against lung cancer radiation therapy

Patients with advanced non-small cell lung cancer can safely take an experimental oral drug intended to protect healthy tissue from the effects of radiation, according to a study led by researchers at the University of Pittsburgh Cancer Institute and published in this month's issue of Human Gene Therapy.

23 Mar 2011

CytRx commences INNO-206 Phase 1b trial in advanced solid tumors

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that it has initiated an open-label Phase 1b safety and dose escalation clinical trial with INNO-206 at the Sarcoma Oncology Center in Santa Monica, California. The clinical trial will include up to 24 patients with advanced solid tumors who have failed standard therapies.

17 Mar 2011

Inovio signs agreement with OncoSec to sell non-DNA cancer vaccine technology

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that it has signed an agreement with OncoSec Medical Inc. providing for the sale to OncoSec of certain non-DNA vaccine technology and intellectual property relating to electroporation technology useful for electrochemical and cytokine based immune therapies for treating solid tumors.

17 Mar 2011

Scientists to develop new universal vaccine against various flu viruses

A vaccine that helps against all types of influenza - for several years? If all goes right for Norwegian company Bionor Pharma ASA, such a vaccine could exist within a few years.

17 Mar 2011

Additional research needed for oral PrEP to treat HIV

The first human studies of an oral drug regimen to prevent HIV infection in high-risk individuals yielded a promising near 50% reduction in HIV incidence, but a number of issues require additional research before oral pre-exposure prophylaxis can be implemented on a large scale, according to an article in AIDS Patient Care and STDs, a peer-reviewed journal published by Mary Ann Liebert, Inc.

15 Mar 2011

OncoSec signs agreement with Inovio to purchase non-DNA cancer vaccine technology

OncoSec Medical Inc., a developer of innovative and proprietary medical approaches to treat solid tumor cancers with unmet medical needs, announced today that it has signed an agreement with Inovio Pharmaceuticals, Inc. providing for the purchase by OncoSec of certain non-DNA vaccine technology and intellectual property relating to electroporation technology useful for electrochemical and cytokine based immune therapies for treating solid tumors.

15 Mar 2011

Biodel selects BIOD-105, BIOD-107 recombinant human insulin formulations for clinical testing, development

Biodel Inc. announced today that it has selected two new formulations of recombinant human insulin for clinical testing and is accelerating clinical development plans of these mealtime insulin drug candidates. The new formulations, BIOD-105 and BIOD-107, are designed to result in more rapid insulin action compared to currently marketed meal time insulin analogs while maintaining an injection site tolerability profile comparable to currently marketed insulins.

14 Mar 2011

Alzheimer's vaccine - First evidence for efficacy

AFFiRiS' Alzheimer's vaccine candidate AD02 showed indicative evidence for potential efficacy in a phase I clinical trial. This was demonstrated by the analysis of the data from secondary clinical study endpoints.

12 Mar 2011

Adamis submits APC-100 IND to FDA for treatment of prostate cancer

Adamis Pharmaceuticals Corporation announced today that it has recently submitted to the FDA an Investigational New Drug application for APC-100 to treat prostate cancer.

9 Mar 2011

Galderma, Astrazeneca collaborate to develop new compounds for dermatological disorders

AstraZeneca and Galderma Pharma S.A., a global speciality pharmaceutical company focused on dermatology, today announced they have entered into a R&D collaboration to develop new treatments for dermatological conditions including psoriasis, acne and atopic dermatitis which significantly affect the health and quality of life for millions of people worldwide.

7 Mar 2011

Achillion fourth quarter revenue is $2 million for three months ended December 31, 2010

Achillion Pharmaceuticals, Inc., a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today reported financial results for the three and twelve months ended December 31, 2010.

2 Mar 2011

Advion to establish new laboratory at Purdue Research Park near Indianapolis

Advion BioServices Inc., a provider of contract bioanalytical research services, announced that it will establish a laboratory here, creating 49 immediate jobs and up to 66 jobs by 2015.

From Advion 2 Mar 2011